On January 6, 2020 BioMarker Strategies, LLC, a company focused on helping make precision medicine more of a reality for patients with solid tumor cancers, reported that President and CEO Jerry Parrott will present at Biotech Showcase on Wednesday, January 15 at 10:15 AM PST (Press release, BioMarker Strategies, JAN 6, 2020, View Source [SID1234552740]). The presentation will take place in Franciscan C, Ballroom Level, Hilton San Francisco Union Square.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Parrott will also participate in the Life Sciences Nation’s RESI at San Francisco conference, which takes place on Tuesday January 14 at the Marines’ Memorial Club & Hotel, and in the BIO One on One Partnering at JPM program, which is organized by the Biotechnology Innovation Industry (BIO), with meeting space available at the San Francisco Marriott Marquis.
These events take place in parallel to the annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry with more than 9,000 attendees. Other biotechnology, pharmaceutical and life sciences events, including the ones mentioned above, have been also been attracted to San Francisco for what has come to be known to many as JPM Week. For many biotechnology, pharmaceutical and life sciences companies, fund-raising and business development efforts for each year begin with JPM week.
BioMarker Strategies has developed the patented SnapPath Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for solid tumors. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for ex vivo exposure to immunotherapies and targeted therapies, either alone or in combination. This enables the generation of PathMap Functional Signaling Profiles, which are highly predictive tests for assessing individual solid tumor response to these treatments, because they are based on the dynamic, predictive signaling information available only from live cells.